Nizatidine

From Wikipedia, the free encyclopedia

Nizatidine
Systematic (IUPAC) name
N-[2-(2-dimethylaminomethylthiazol- 4-ylmethylthio)ethyl]-N'-methyl- 2-nitrovinylidenediamine
Identifiers
CAS number	76963-41-2
ATC code	A02BA04
PubChem	3033637
DrugBank	APRD00706
Chemical data
Formula	C12H21N5O2S2
Mol. weight	331.46 g/mol
Pharmacokinetic data
Bioavailability	>70%
Protein binding	35%
Metabolism	Hepatic
Half life	1-2 hours
Excretion	Renal
Therapeutic considerations
Licence data	US
Pregnancy cat.	B3(AU)
Legal status	S4(AU) POM(UK)
Routes	Oral

Nizatidine is a histamine H₂-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.

[edit] Clinical use

Main article: H2-receptor antagonist

Certain preparations of nizatadine are now available over the counter in various countries including the United States.

[edit] History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.

Nazitidine proved to be the last new histamine H₂-receptor antagonists introduced prior to the advent of proton pump inhibitors.

H2-receptor antagonists (A02BA) edit
Cimetidine, Famotidine, Nizatidine, Ranitidine, Roxatidine